First Solar, Inc. (FSLR) Stock Price Today
Aura AI Summary
Key Stats
- $24.05BMarket Cap
- -Volume
- TechnologySector
- $318.3052W High
- $166.8252W Low
- -Typical Hold Time
- $22.21BEnterprise Value
- -Div Yield
- -Trading Activity
Track First Solar, Inc. (FSLR) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, First Solar, Inc. has traded between a low of $166.82 and a high of $318.3, highlighting its annual price range. Buy and sell First Solar, Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About First Solar, Inc.
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and a new factory under construction in India.
Most Recent News
Aduro and ECOCE complete Phase 1 of mapping flexible plastic waste in Mexico, starting HCT testing for circular recycling.
Aduro Clean Technologies and ECOCE have successfully completed Phase 1 of mapping flexible and multilayer plastic waste streams in Mexico, estimated at 1.5 million tons annually. The project now moves into testing these materials using Aduro's Hydroc...

Aduro and ECOCE advance to HCT testing for recycling Mexico's flexible plastic waste streams.
Aduro Clean Technologies and ECOCE have completed phase 1 of mapping flexible plastic waste streams in Mexico, estimated at 1.5 million tonnes annually. They are now moving selected post-consumer flexible packaging materials into Hydrochemolytic™ (HC...

FDA approves Fabhalta as first drug to significantly slow kidney decline in IgAN patients
The FDA has granted traditional approval to Fabhalta (iptacopan), a first-in-class complement inhibitor, for slowing kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN). Fabhalta showed a 48% slower decline in kidney fu...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.